CT增强联合免疫组化指标诊断肺癌的研究

CT enhancement combining with immunohistochemistry signs in diagnosis of lung cancer

目的研究肺癌环氧化酶2(COX-2)、血管内皮生长因子(VEGF)、微血管密度(MVD)表达与CT增强表现相关性。方法对经病理证实25例肺癌及35例肺良性病变行CT增强扫描,并应用PV法对其病理标本进行免疫组化分析,并研究COX-2、VEGF、MVD表达水平与肺癌CT增强峰值、组织学类型、临床分期、淋巴结转移及分化程度之间的关系。结果肺癌组COX-2、VEGF、MVD表达水平及CT增强峰值明显高于肺良性病变组;COX-2、VEGF、MVD表达水平与肺癌组织学类型、临床分期、淋巴结转移及CT增强峰值之间密切相关,与肺癌的分化程度无关。结论COX-2、VEGF、MVD可作为临床评价肿瘤发展,估计肿瘤预后的重要分子生物学指征。CT增强检查可以反映肺癌的血供特点,可根据增强峰值来推测肿瘤的侵袭、转移及预后情况。

Objective To study the relationship between the expression of COX-2, VEGF, MVD and CT enhanced appearances of lung cancer. Methods Dynamic CT scans were used to evaluate respectively in 35 patients with benign disease and 25 patients with lung cancer who underwent complete resection and had not received any chemotherapy or radiotherapy prior to operation. The PV method was used to detect the expression level of COX-2, VEGF and MVD in all these cases. We wanted to research the relationship between the CT enhancement value, histological types, clinic stages, lymph nodes metastasis, differentiation grades and expression of the three immunochemical signs. Results Expression level of COX-2, VEGF, MVD and CT enhancement value in lung carcinoma group were higher than those in contrast group, expression level of COX- 2, VEGF and MVD related to the CT enhancement value, histological types, clinic stages and lymph nodes metastasis, but had no relationship with differentiation grades of lung cancer. Conclusion COX-2, VEGF and MVD may be important mo- lecular biology predictors in the early diagnosis of lung cancer and can evaluate prognosis of patients with lung cancer. Dynamic CT enhancement scans can reflect the vascularity characteristic of lung cancer. We can predict the involvement, metastasis and prognosis of lung carcinoma according to the enhancement value of dynamic CT.